Mebendazolo Oral Tablets, chewable 100 mg Mebendazolo Tablets, Copley Vermox®, Janssen AHFS DRUG INFORMATION® (2004)
Mebendazolo when given in typical doses has not been associated with serum enzyme elevations, although the duration of therapy is usually short and monitoring for enzyme elevations has rarely been reported. With high dose therapy (which is now rarely used with the availability of albendazole), elevations in serum aminotransferase levels (2 to 10 times normal) can occur, but are usually well tolerated. There have been rare reports of acute liver injury due to mebenazole, particularly when it is given repeatedly or in higher doses. The onset is usually with fever and malaise within days of starting or restarting therapy. The pattern of serum enzyme elevations is typically hepatocellular and jaundice is uncommon. The abnormalities usually resolve rapidly with stopping therapy. Signs of hypersensitivity (rash, fever and eosinophilia) are typical and liver biopsy may show granulomas.
Likelihood score: D (possible cause of clinically apparent liver injury).
6. How to cope with s >
What to do about:
- stomach pain – try to rest. It can help to eat and drink slowly and have smaller and more frequent meals. Placing a heat pad or covered hot water bottle on your stomach may also help. If you are in a lot of pain, speak to a doctor or pharmacist.
- stomach discomfort including wind – stick to simple meals and avoid rich or spicy food. It might help to take Mebendazolo after you’ve eaten to see if that helps ease the symptoms.
- diarrhoea – drink plenty of water or other fluids to avoid dehydration. Signs of dehydration include peeing less than usual or having strong-smelling pee. Do not take any other medicines to treat diarrhoea without speaking to a pharmacist or doctor first.
There is a potential for development of resistance to Mebendazolo. The mechanism of resistance to Mebendazolo is likely due to changes of beta-tubulin protein, which reduces binding of Mebendazolo to beta-tubulin; however, the clinical significance of this is not known.
The plasma protein binding of Mebendazolo is 90 to 95%. The volume of distribution is 1 to 2 L/kg, indicating that absorbed Mebendazolo penetrates areas outside the vascular space.
On this page
- About Mebendazolo
- Key facts
- Who can and cannot take Mebendazolo
- How and when to take it
- Side effects
- How to cope with side effects
- Pregnancy and breastfeeding
- Cautions with other medicines
- Common Questions
Concomitant use of Mebendazolo, including VERMOX., and metronidazole should be avoided .
Although metronidazole generally is the drug of choice for the treatment of giardiasis caused by Giardia lamblia, Mebendazolo has been used for the treatment giardiasis in a limited number of adolescents and children.
How can i get Mebendazolo online over the counter?
You can buy Mebendazolo OTC in online drugstore with low cost.
Mebendazolo is used for the treatment of trichuriasis caused by Trichuris trichiura (whipworm). Mebendazolo is considered a drug of choice for the treatment of trichuriasis.
Mechanism Of Action
Mebendazolo, a benzimidazole, is an anthelmintic drug .
Do not take EMVERM if you are allergic to Mebendazolo or any of the ingredients in EMVERM. See the end of this Patient Information for a complete list of ingredients in EMVERM.
- are pregnant or plan to become pregnant. It is not known if EMVERM will harm your unborn baby.
- are breastfeeding or plan to breastfeed. EMVERM can pass into your milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take EMVERM. Do not breastfeed while taking EMVERM.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using EMVERM with certain other medicines can change the way these medicines act, causing serious side effects. Know the medicines you take. Keep a list of them to show to your healthcare provider or pharmacist when you get a new medicine.
Mixing Mebendazolo with herbal remedies or supplements.
There might be a problem with taking some herbal remedies and supplements together with Mebendazolo. Ask a pharmacist or doctor for advice.
There is no evidence that Mebendazolo, even at high doses, is effective for hydatid disease. There have been rare reports of neutropenia and agranulocytosis when Mebendazolo was taken for prolonged periods and at dosages substantially above those recommended.
Mebendazolo , a synthetic benzimidazole, is the agent used most widely in the U.S. for treatment of intestinal helminthiasis, including ascariasis, hookworm infection, trichuriasis, trichostrongyliasis, and enterobiasis. Regimens of Mebendazolo consisting of a single high dose generally yield lower cure rates compared with regimens of single-dose albendazole. Treatment of capillariasis, infection with a nematode that is rare outside a circumscribed area of the Philippines, requires administration of Mebendazolo orally for 20 days, but albendazole generally is preferred for this indication. High-dose Mebendazolo often is used as a secondary agent in the treatment of trichinellosis; systemic corticosteroids must be used concomitantly. Because neither DEC nor ivermectin is effective against Mansonella perstans infection, Mebendazolo is thought to be the optimal treatment. 70 Mebendazolo has been used in the past to treat Angiostrongylus cantonensis, Gnathostoma spinigerum, and echinococcal disease. Due to the poor tissue penetration of Mebendazolo and the current availability of albendazole in all countries, Mebendazolo should no longer be used for these indications.
Mebendazolo binds irreversibly to colchicine-sensitive sites on tubulin, blocking microtubule assembly. Glucose uptake by the organism is thus inhibited without an effect on serum glucose levels in humans. Because of poor gastrointestinal tract absorption ( 71 There are no data on the agent's excretion in human milk, but little is excreted in animal milk; caution is indicated but breastfeeding women can be treated if necessary. Pediatric dosage is identical to adult dosage. Mebendazolo is teratogenic in rats and generally has been avoided during pregnancy. Data now suggest no increase in major congenital defects, so Mebendazolo can be recommended for use in the second and third trimesters if absolutely necessary. 72
The elimination half-life of Mebendazolo has been reported to be about 2.8-9 hours. Although the exact metabolic fate of Mebendazolo has not been fully determined, the drug is metabolized via decarboxylation to 2-amino-5(6)-benzimidazolyl phenylketone; this metabolite does not have anthelmintic activity. Approximately 2-10% of an oral dose of Mebendazolo is excreted in urine within 24-48 hours of administration, principally as unchanged drug and the 2-amino metabolite. The metabolic fate and rate of excretion of unabsorbed Mebendazolo have not been determined.
5.2 Inhibition of glucose uptake
Mebendazolo interferes with glucose uptake in nematodes and cestodes. The uptake of exogenous glucose in A. suum and M. expansa is inhibited by Mebendazolo. The inhibition of glucose transport in A. suum and T. spiralis larvae at 10 − 5 - 10 − 6 M concentration of Mebendazolo has also been demonstrated . The blocking of glucose utilisation or its transport leads to decreased ATP synthesis causing depletion of the energy source in the worm.
Further work on the mode of action of benzimidazoles has shown that drugs of this class interfere with the energy pathway of the helminths by inhibiting both cytoplasmic and mitochondrial malate dehydrogenase (MDH) . The cytoplasmic and mitochondrial MDH obtained from A. suum, F. hepatica and M. expansa was inhibited by Mebendazolo, while albendazole, parbendazole and thiabendazole inhibited the F. hepatica enzymes more than the enzyme from A. suum . According to McCracken and Stilwell , the benzimidazole anthelmintics may act as lipid-soluble proton conductors both in artificial (phospholipid bilayer) and natural (rat-liver mitochondria) membrane systems. These drugs disturb the transmembrane proton gradient severely, leading to a considerable drop in cellular ATP levels. The in vitro and in vivo results obtained by these authors would indicate that the mode of action of benzimidazole may be, in part, due to a bioenergetic disruption caused by transmembrane proton discharge.